Clinical and epidemiologic principles of anthrax

Emerging Infectious Diseases

Volumn 5, Issue 4, 1999, Pages 552-555

  Cieslak, Theodore J ^a   Eitzen Jr , Edward M ^a,b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DOXYCYCLINE;

ANTHRAX; ANTIBIOTIC THERAPY; BACILLUS ANTHRACIS; BACTERIUM IDENTIFICATION; CHEMOPROPHYLAXIS; DOSE RESPONSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PREVALENCE; REVIEW;

EID: 0032870323     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0504.990418     Document Type: Review

References (20)

1. Exodus 9:1-12.
2. Pasteur L, Chamberlain C-E, Roux E. Compte rendu sommaire des experiences faites a Pouilly-le-Fort, pres Melun, sur la vaccination charbonneuse [French]. Comptes Rendus des seances De L'Academie des Sciences 1881;92:1378-83.
3. Turner M. Anthrax in humans in Zimbabwe. Cent Afr J Med 1980;26:160-1.
4. Harrison LH, Ezzell JW, Abshire TG, Kidd S, Kaufmann AF. Evaluation of serologic tests for diagnosis of anthrax after an outbreak of cutaneous anthrax in Paraguay. J Infect Dis 1989;160:706-10.
5. Report of a WHO group of consultants. Health aspects of chemical and biological weapons. Geneva: World Health Organization; 1970. p. 97-9.
6. Science Applications International Corporation. Effectiveness of medical intervention against battlefield levels of Bacillus anthracis. 1993.
7. Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A, Yampolskaya O, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994;266:1202-7.
8. Turell MJ, Knudson GB. Mechanical transmission of Bacillus anthracis by stable flies and mosquitoes. Infect Immun 1987;55:1859-61.
9. Titball RW, Turnbull PCB, Hutson RA. The monitoring and detection of Bacillus anthracis in the environment. Journal of Applied Bacteriology 1991; Suppl 70.9S-18.
10. Coker PR, Smith KL, Hugh-Jones ME. Anthrax in the USA. Proceedings of the Third International Conference on Anthrax, Plymouth, England, September 7-10, 1998:44 [abstract].
11. Sidell FR, Patrick WC, Dashiell TR, editors. Jane's chem-bio handbook. Alexandria (VA): Jane's Information Group; 1998. p. 229-44.
12. Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 1997. MMWR Morb Mortal Wkly Rep 1998;46:74.
13. Gill DM. Seven toxic peptides that cross cell membranes. In: Jeljaszewicz J, Walstrom T, editors. Bacterial toxins and cell membranes. New York: Academic Press; 1978. p. 291-332.
14. Brachman PS, Friedlander AM. Anthrax. In: Plotkin & Mortimer, editors. Vaccines. Philadelphia (PA): W.B. Saunders; 1994. p. 730.
15. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A 1993;90:2291-4.
16. Lightfoot NF, Scott RJD, Turnbull PCB. Antimicrobial susceptibility of Bacillus anthracis. Salisbury Medical Bulletin Suppl 1990;68:95-8.
17. Kelly DJ, Chulay JD, Mikesell P, Friedlander AM. Serum concentrations of penicillin, doxycycline, and ciprofloxacin during prolonged therapy in rhesus monkeys. J Infect Dis 1992;166:1184-7.
18. Friedlander AM, Welkos SL, Pitt MLM, Ezzell JW, Worsham PL, Rose KJ, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993;167:1239-42.
19. Centers for Disease Control and Prevention. Bioterrorism alleging use of anthrax and interim guidelines for management-United States, 1998. MMWR Morb Mortal Wkly Rep 1999;48:69-74.
20. Sanchez R. California anthrax threats spawn costly wave of fear. Washington Post, January 11, 1999, section A, page 1.